Market Research Reports and Industry Reports

India Pharma Outlook 2016: Milestones to Watch Growth from Exports and Domestic Getting Better, Implementation of Policies under Make-in-India, Overture of A New Ministry

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
2016 will be a crucial for drug makers and consumers. During Make-in-India week in Mumbai, Govt. highlighted many amendments or introduction of new policies with an aim to make India as a major hub for end to end drug discovery. To boost drug discovery, to promote manufacturing of certain drugs against life threatening diseases like AIDS, and to reduce our dependence on China, the Govt. has promised to offer many incentives (exemption from excise duty or tax) and also plans to setup venture capital funds, cluster developments to strengthen pharma infrastructure / business. Other developments or initiatives include, i) The voluntary Uniform code of Pharma marketing practice will be replaced with a mandatory code by June. This will stop the promotion of drug prior to receipt of the marketing approval and also the practice of drug makers offering gifts to doctors upon prescribing their products; ii) Concept of the Online pharmacies is also expected to be implemented during this year; iii) Change in FDI rule where investor now invest thru Automatic route rather taking any prior regulatory approval; iv) Growth in Medical Infrastructure which will increase accessibility to drug market to improve in Tier-II towns and rural areas.

Declined growth in bulk drugs due to regulatory scrutiny and rising competition & market factors from other Asian competing nations will be compensated by geographies expansion (e.g., Lupin, Cipla, Sun pharma) and sustainable growth from Domestic formulation (e.g. Alkem, Cipla, Sun pharma, Dr Reddy), mainly from Chronic diseases segment, due to growth in urban population, better awareness on healthcare, and greater penetration of services. India pharma has started expanding in other regulated markets (Japan, Germany, France, Canada) and Tier-II countries (Brazil, Mexico, Venezuela, Russia, etc.). To explore further opportunities of growth, Indian pharma companies have started developing complex generics/ biosimilars. Almost all companies, among Top-20 list, have robust pipeline in this value chain, targeting primarily emerging markets; however, they are also capitalizing on their competitiveness and capabilities to enter into the regulated market.
Figure 1 :Cipla Ltd.
GENERIC NEXIUMS MARKET SHARE TREND
Figure 1:Dr. Reddys Lab PENDING ANDAs(76) BY DOSAGE FORM& SELECT OPPORTUNITIESFigure 2
Dr. Reddys Lab
AURIGENE: INTERNAL PIPELINE
Figure 1 :Lupin Limited COMBINED ENTITY: LUPIN + GAVIS
Figure 2 :Lupin Limited INCREASED COMPETITION LED TO DECLINED MARKET SHARE IN US




List Of Tables

Table 1 :Aurobindo Pharma GLOBAL REGULATORY FILINGS
Table 2 :Aurobindo Pharma KEY ANDAs APPROVAL IN 1H16
Table 1 :Cadila Healthcare Ltd.
KEY TRANSDERMAL PRODUCTS
Table 1 :Cipla Ltd.
INVAGENS SELECT PARA IV OPPORTUNITIES
Table 2 :Cipla Ltd.
INVAGEN: HIGHEST MARKET SHARE PRODUCTS TOP 5
ANNEXURE I : Cipla Ltd. INVAGENS CURRENT PRODUCTS
Table 1 :Dr Reddys Ltd.FACING COMPETITION IN US: MARKET SHARE OF KEY INJECTABLES
Table 1 :Lupin Limited NET SALES MIX: 2QFY16
Table 2 :Lupin Limited US APPROVALS IN 9MFY16
Table 3 :Lupin Limited US: SELECT UPCOMING ANDAs OPPORTUNITIES
Annexure I :
Lupin Limited
2QFY16: SALES BREAKUP, GEOGRAPHY-WISE
Annexure II :Lupin Limited LPCS ACQUISITIONS IN OTHER EMERGING MARKETS
Annexure III :Lupin Limited COMBINED CAPABILITIES: GAVIS + LUPIN
Annexure II
Lupin Limited
PORTFOLIO OF APPROVED DRUGS: GAVIS + NOVEL LAB
Table 1 :NATCO Pharma KEY ANDAs PIPELINE







List Of Figures

Figure 1 :Cipla Ltd.
GENERIC NEXIUMS MARKET SHARE TREND
Figure 1:Dr. Reddys Lab PENDING ANDAs(76) BY DOSAGE FORM& SELECT OPPORTUNITIESFigure 2
Dr. Reddys Lab
AURIGENE: INTERNAL PIPELINE
Figure 1 :Lupin Limited COMBINED ENTITY: LUPIN + GAVIS
Figure 2 :Lupin Limited INCREASED COMPETITION LED TO DECLINED MARKET SHARE IN US




2017 India Automated Microbiology Market: Molecular Diagnostics, Identification, Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics-- Specimen, Test, and Sales Forecasts, Competitive Strategies, Opportunities

This new report examines current and emerging assays; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over

USD 4850View Report

2017 India Molecular Diagnostics Market: Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing--Test Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation, Opportunities

This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the molecular diagnostics market during the next five years.Highlights- Five-year test

USD 4250View Report

2017 India Infectious Disease Testing Market: Volume and Sales Forecasts for 100 Tests, Competitive Strategies, Innovative Technologies, Opportunities for Suppliers

This new report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the infectious disease testing market during the next five

USD 4500View Report

Global Pharmaceutical & Biotechnology Outlook 2013: India Pharma

India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also benefited from the continuing high

USD 2500View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 1500
  • Site Licence    $ 3000
  • Enterprisewide Licence    $ 4500
$ 1500

Reports Details

Published Date : Mar 2016
No. of Pages :35
Country :India
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment